APLS-38.90%20.0%
ARQT+56.90%20.0%
CYTK+100.42%20.0%
HALO+50.61%20.0%
SPRY-59.22%20.0%
As of Aug 24, 2026, 4:53 AM ET
Biotech '25: Commercial / Late Stage Constituents
Apellis Pharmaceuticals, Inc.APLS | 20.0% | 0.00% | 0.00% | 0.00% | 0.00% | -31.97% | -18.46% | -25.70% | -57.39% | -72.36% | -38.90% | $2.19B |
Arcutis Biotherapeutics, Inc.ARQT | 20.0% | -1.07% | -4.38% | -8.30% | -6.63% | -13.64% | -7.01% | 51.08% | 155.14% | 19.26% | 56.90% | $3.14B |
ARS Pharmaceuticals, Inc.SPRY | 20.0% | 0.00% | -7.48% | -7.32% | 7.31% | -52.75% | -40.68% | -57.82% | -57.52% | -80.07% | -59.22% | $546.7M |
Cytokinetics, IncorporatedCYTK | 20.0% | -0.44% | 0.51% | -4.83% | -0.38% | 20.93% | 23.50% | 90.91% | 34.05% | 144.79% | 100.42% | $9.56B |
Halozyme Therapeutics, Inc.HALO | 20.0% | 1.93% | 5.41% | 32.03% | 31.05% | 60.73% | 55.57% | 71.64% | 72.46% | 165.77% | 50.61% | $12.83B |
| Theme return | — | 0.08% | -1.19% | 1.48% | 6.89% | -6.25% | 1.32% | 26.75% | 28.99% | 59.63% | 14.22% | — |
| Average | 20.0% | 0.08% | -1.19% | 2.32% | 6.27% | -3.34% | 2.58% | 26.02% | 29.35% | 35.48% | 21.96% | $5.65B |
| Median | 20.0% | 0.00% | 0.00% | -4.83% | 0.00% | -13.64% | -7.01% | 51.08% | 34.05% | 19.26% | 50.61% | $3.14B |
| Std Dev | 0.0% | 1.00% | 4.42% | 15.13% | 13.15% | 40.15% | 33.62% | 57.66% | 80.96% | 104.09% | 60.81% | $4.72B |
| Min | 20.0% | -1.07% | -7.48% | -8.30% | -6.63% | -52.75% | -40.68% | -57.82% | -57.52% | -80.07% | -59.22% | $546.7M |
| Max | 20.0% | 1.93% | 5.41% | 32.03% | 31.05% | 60.73% | 55.57% | 90.91% | 155.14% | 165.77% | 100.42% | $12.83B |
| % Positive Tickers | 20.00% | 40.00% | 20.00% | 40.00% | 40.00% | 40.00% | 60.00% | 60.00% | 60.00% | 60.00% |
Default: Wgt ↓ · Click headers to sort · Shift+click secondary
About this theme
Biotech '25: Commercial / Late Stage tracks 5 publicly listed stocks in this theme: APLS, ARQT, CYTK, HALO, SPRY. See the constituent table for details.